financetom
Business
financetom
/
Business
/
Elf Beauty lifts annual forecasts as cosmetic, skincare demand holds up
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Elf Beauty lifts annual forecasts as cosmetic, skincare demand holds up
Aug 8, 2024 1:31 PM

By Granth Vanaik

(Reuters) - Elf Beauty ( ELF ) raised annual sales and profit forecasts after topping first-quarter estimates on Thursday, as more customers visited stores and websites to buy its affordable cosmetics and skincare products.

Beauty company Elf, like its peers in the segment, has sustained the post-pandemic boom in demand, as low-cost products from its brands such as Naturium, Skin, and Cosmetics continue to attract customers, including those having strained budgets due to a sticky inflation.

Retailers, such as Target, which house Elf's products, have also seen sales surge for beauty products in recent months.

"We have seen consumers are getting choosier, but they're choosing Elf," CEO Tarang Amin told Reuters.

Elf's stock, however, has dropped about 14% quarter-to-date, after investors raised concerns around possibility of rising tariffs on imports of its nearly 80% finished products manufactured in China and higher ocean freight costs, among other factors.

CEO Amin said that an increase in tariffs on imports from China, if Republican presidential candidate Donald Trump comes to power, would mostly impact the company in fiscal 2026.

Earlier this year, Trump had floated the idea of imposing tariffs on China again if he wins the presidential election in November and said the rate for such tariffs could exceed 60%.

"We don't like 60% tariff just because we feel it is a tax on American consumers," Amin said, adding, the tariffs impact would be addressed by raising product prices and diversifying supply chain operations.

Elf now sees 2025 sales to be between $1.28 billion and $1.30 billion, compared to previous expectations of $1.23 billion and $1.25 billion.

It now expects annual adjusted per-share profit to be between $3.36 and $3.41, versus prior projections of $3.20 and $3.25.

Net sales rose 50% to $324.5 million in the quarter ended June 30, beating estimates of about $304.7 million. Adjusted profit of $1.10 per share also topped LSEG expectations of 84 cents.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Freeport-McMoRan expects lower consolidated sales for copper, gold in third quarter
Freeport-McMoRan expects lower consolidated sales for copper, gold in third quarter
Sep 24, 2025
Sept 24 (Reuters) - Miner Freeport-McMoRan said on Wednesday that it was expecting consolidated sales to be about 4% lower for copper and nearly 6% lower for gold in the third quarter, compared with its prior forecast. (Reporting by Pooja Menon in Bengaluru; Editing by Anil D'Silva) ...
Two US senators urge Tinder parent to act against dating scams on its apps
Two US senators urge Tinder parent to act against dating scams on its apps
Sep 24, 2025
(Reuters) -Two U.S. senators sent a letter to Tinder parent Match on Wednesday, pushing for action against dating scams on the company's platforms and asking for information about its efforts to detect frauds and protect its users. In a letter to Match CEO Spencer Rascoff, Democratic Senator Maggie Hassan and Republican Senator Marsha Blackburn asked the company to provide documents...
Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial
Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial
Sep 24, 2025
Sept 24 (Reuters) - Harmony Biosciences ( HRMY ) said on Wednesday its experimental drug for a type of rare genetic disorder failed to meet the main goal in a late-stage trial. ...
Biogen Says Leqembi Approved in Australia as Treatment for Alzheimer's Disease; Shares Up Pre-Bell
Biogen Says Leqembi Approved in Australia as Treatment for Alzheimer's Disease; Shares Up Pre-Bell
Sep 24, 2025
08:11 AM EDT, 09/24/2025 (MT Newswires) -- Biogen (BIIB) and Eisai said Wednesday that Australia's Therapeutic Goods Administration approved Leqembi for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease. The approval follows a review process after the regulatory agency initially did not approve the drug in February, the company said. Leqembi targets toxic protofibrils and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved